放射性勃起功能障碍:近期进展与未来方向
综述总结前列腺癌放疗后放射性勃起功能障碍(RiED)的研究进展,指出放疗后5年内约50%患者可能发生RiED,涉及动脉形态损伤、海绵体神经运动功能下降及放射基因组学生物标志物,并讨论质子束治疗、干细胞疗法、冲击波治疗等新型干预策略。
要点
- 前列腺癌放疗后5年内约50%患者可能发生RiED。
- 前列腺放疗可致阴部内动脉形态损伤及海绵体神经运动功能下降。
- 放射基因组学生物标志物有望监测放射性晚毒性及神经损伤。
核心结论
- RiED是前列腺癌放疗后显著影响生活质量的晚期副作用,其精确机制尚在探索中。
- 放射基因组学、质子束治疗及干细胞疗法等新型策略可能用于减轻或治疗放疗后性功能障碍。
研究设计与样本
- 综述总结RiED研究进展、新型治疗模式及可能分子机制。
主要发现
- 前列腺放疗诱导显著动脉形态损伤伴阴部内动脉张力异常改变。
- 前列腺放疗降低海绵体神经运动功能,可能与轴突变性相关。
- 放射诱导体细胞突变识别、拷贝数变异及全基因组关联研究促进生物标志物发现。
关键数值与推荐
- 放疗后5年内约50%患者可能发生RiED。
临床怎么用
- 基因组与蛋白质组生物标志物可能改善治疗并减少动脉组织与神经损伤。
- 质子束治疗可精准靶向肿瘤并显著减少对重要器官和健康组织的脱靶损伤。
- 干细胞疗法、冲击波治疗、组织工程神经移植及营养补充可能减轻或治愈放疗后性功能障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer is one of the most prevalent cancers and the second leading cause of cancer-related deaths in men in the United States. A large number of patients undergo radiation therapy (RT) as a standard care of treatment; however, RT causes erectile dysfunction (radiation-induced erectile dysfunction; RiED) because of late side effects after RT that significantly affects quality of life of prostate cancer patients. Within 5 years of RT, approximately 50% of patients could develop RiED. Based on the past and current research findings and number of publications from our group, the precise mechanism of RiED is under exploration in detail. Recent investigations have shown prostate RT induces significant morphologic arterial damage with aberrant alterations in internal pudendal arterial tone. Prostatic RT also reduces motor function in the cavernous nerve which may attribute to axonal degeneration may contributing to RiED. Furthermore, the advances in radiogenomics such as radiation induced somatic mutation identification, copy number variation and genome-wide association studies has significantly facilitated identification of biomarkers that could be used to monitoring radiation-induced late toxicity and damage to the nerves; thus, genomic- and proteomic-based biomarkers could greatly improve treatment and minimize arterial tissue and nerve damage. Further, advanced technologies such as proton beam therapy that precisely target tumor and significantly reduce off-target damage to vital organs and healthy tissues. In this review, we summarize recent advances in RiED research and novel treatment modalities for RiED. We also discuss the possible molecular mechanism involved in the development of RiED in prostate cancer patients. Further, we discuss various readily available methods as well as novel strategies such as stem cell therapies, shockwave therapy, nerve grafting with tissue engineering, and nutritional supplementations might be used to mitigate or cure sexual dysfunction following radiation treatment.
引用
- Mahmood J, Shamah AA, Creed TM, et al. Radiation-induced erectile dysfunction: Recent advances and future directions. Adv Radiat Oncol. 2016. PMID: 28740886. doi:10.1016/j.adro.2016.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。